Soleil Securities Upgrades Varian Medical Systems (VAR) to Buy; Raises FY10-11 Estimates & PT
VAR Hot Sheet
Rating Summary:10 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Soleil Securities upgrades Varian Medical Systems (NYSE: VAR) from Hold to Buy. Price target increased from $35 to $52.
Soleil analyst says, "We're raising our rating on Varian Medical Systems from Hold-to-Buy as final 2010 reimbursement rates for radiation oncology are better-than-expected. Bottom-Line: We see the unexpected reversal of draconian reimbursement cuts helping VAR's business sooner-versus-later...We're raising FY10E sales/EPS to $2,331.9MM (vs. Street $2,304.0MM) and $2.80 (vs. Street $2.72)--we're raising FY11E sales/EPS to $2,448.6MM (vs. Street $2,439.6MM) and $3.00 (vs. Street $2.99)."
To see more analyst ratings on VAR Click Here.
Varian Medical Systems, Inc. provides cancer therapy systems worldwide.
Soleil analyst says, "We're raising our rating on Varian Medical Systems from Hold-to-Buy as final 2010 reimbursement rates for radiation oncology are better-than-expected. Bottom-Line: We see the unexpected reversal of draconian reimbursement cuts helping VAR's business sooner-versus-later...We're raising FY10E sales/EPS to $2,331.9MM (vs. Street $2,304.0MM) and $2.80 (vs. Street $2.72)--we're raising FY11E sales/EPS to $2,448.6MM (vs. Street $2,439.6MM) and $3.00 (vs. Street $2.99)."
To see more analyst ratings on VAR Click Here.
Varian Medical Systems, Inc. provides cancer therapy systems worldwide.
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer
- UPDATE: UBS Upgrades Assured Guaranty (AGO) to Buy; Opportunity Opens After Recent Dip on Moody's Review
Create E-mail Alert Related Categories
UpgradesRelated Entities
Soleil SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
